Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2012 Financial Results Teleconference and Webcast

  Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2012
  Financial Results Teleconference and Webcast

Business Wire

HENDERSON, Nev. -- February 12, 2013

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully
integrated commercial and drug development operations with a primary focus in
hematology and oncology, today announced it will host a teleconference and
webcast with management to discuss the fourth quarter and fiscal year 2012
financial results, provide an update on the Company's business, and discuss
expectations for the future.

Conference Call

     Thursday, February 21, 2013 @ 1:30 p.m. Eastern/10:30 a.m. Pacific
                               
          Domestic:                  (877) 837-3910, Conference ID# 94256900
                                     
          International:             (973) 796-5077, Conference ID# 94256900
                                     

For interested individuals unable to join the call, a replay will be available
from February 21, 2013 @ 4:30 p.m. ET/1:30 p.m. PT through March 07, 2013
until 11:59 p.m. ET/8:59 p.m. PT.

                                       
          Domestic Replay Dial-In #:               (855) 859-2056, Conference
                                                   ID# 94256900
                                                   
          International Replay Dial-In             (404) 537-3406, Conference
          #:                                       ID# 94256900
                                                   

This conference call will also be webcast. Listeners may access the webcast,
which will be available on the investor relations page of Spectrum
Pharmaceuticals' website: www.sppirx.com on February 21, 2013 @ 1:30 p.m.
ET/10:30 a.m. PT.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary focus
in oncology and hematology. Spectrum and its affiliates market three oncology
drugs ─ FUSILEV^® (levoleucovorin) for Injection in the U.S.; FOLOTYN^®
(pralatrexate injection), also marketed in the U.S.; and ZEVALIN^®
(ibritumomab tiuxetan) Injection for intravenous use, for which the Company
has worldwide marketing rights. Spectrum's strong track record in in-licensing
and acquiring differentiated drugs, and expertise in clinical development have
generated a robust, diversified, and growing pipeline of product candidates in
advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is
available at www.sppirx.com.

Forward-looking statement — This press release may contain forward-looking
statements regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could cause actual
results to differ materially. These statements are based on management's
current beliefs and expectations. These statements include, but are not
limited to, statements that relate to our business and its future, including
certain company milestones, Spectrum's ability to identify, acquire, develop
and commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, leveraging the expertise of partners and employees around
the world to assist us in the execution of our strategy, and any statements
that relate to the intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks that could
cause actual results to differ include the possibility that our existing and
new drug candidates may not prove safe or effective, the possibility that our
existing and new applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that our
existing and new drug candidates, if approved, may not be more effective,
safer or more cost efficient than competing drugs, the possibility that our
efforts to acquire or in-license and develop additional drug candidates may
fail, our lack of sustained revenue history, our limited marketing experience,
our dependence on third parties for clinical trials, manufacturing,
distribution and quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and Exchange
Commission. We do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in this press
release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.^®, FUSILEV^®, FOLOTYN^®, and ZEVALIN^® are
registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliates.
REDEFINING CANCER CARE^™ and the Spectrum Pharmaceuticals logos are trademarks
owned by Spectrum Pharmaceuticals, Inc.

© 2013 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

Contact:

Spectrum Pharmaceuticals
Shiv Kapoor, 702-835-6300
Vice President, Strategic Planning & Investor Relations
InvestorRelations@sppirx.com
 
Press spacebar to pause and continue. Press esc to stop.